📅 March 27–30, 2026
📍 Palacongressi di Rimini
🎪 Booth 23
Sentinel Group – Sentinel Diagnostics, Eureka Lab Division, and PRIMA Lab – will take part in the 53rd AMCLI National Congress, one of Italy’s leading events for clinical microbiology and laboratory diagnostics.
Our presence at the congress will focus on monitoring immunocompromised patients, with particular attention to transplant recipients, through an integrated diagnostic approach that combines therapeutic drug monitoring, early infection detection, and rapid clinical decision support.
Therapeutic and Infection Monitoring: A Complementary Approach
In immunocompromised patients, monitoring is essential to ensure treatment efficacy and prevent complications. Sentinel Group addresses this challenge on two levels: immunosuppressant drug monitoring and viral infection surveillance.
Eureka Lab Division offers LC-MS/MS-based solutions for the quantification of immunosuppressive drugs – including Tacrolimus, Cyclosporine A, Everolimus, Sirolimus, and Mycophenolic Acid – supporting more accurate therapeutic management for patients undergoing immunosuppressive therapy.
Alongside pharmacological monitoring, Sentinel Diagnostics provides automated, ready-to-use PCR assays for the identification, quantification, and monitoring of clinically relevant viral infections in transplant patients, including CMV, BKV, EBV, HSV, HHV, Parvovirus B19, and VZV, contributing to timely infection detection.
SENTiNAT® 200: Efficiency and Automation in the Molecular Laboratory
At the core of Sentinel Diagnostics’ molecular offering is SENTiNAT 200, a sample-to-result platform designed to simplify and standardize laboratory workflows.
The system integrates DNA/RNA extraction, PCR setup, and analysis, enabling the execution of up to 15 different targets and the processing of 48 samples in approximately 4 hours, meeting the speed and efficiency requirements of modern laboratories.
Rapid Diagnosis: The Contribution of PRIMA Lab
PRIMA Lab completes Sentinel Group’s portfolio with a range of rapid diagnostic tests designed to support immediate clinical decision-making.
The tests are available for various applications, including HIV, Group A Streptococcus, CRP, and urinary and vaginal infections. They are suitable for both professional use and home testing, integrating seamlessly into diagnostic pathways where timeliness is crucial.
Meet Us at AMCLI 2026
Participation in AMCLI 2026 reaffirms Sentinel Group’s commitment to developing reliable and integrated diagnostic solutions to support laboratory professionals and the management of complex patients.
📍 Visit us at Booth 23, March 27–30, to learn more about our solutions and discuss the current challenges in diagnostics for immunocompromised patients